Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R
dc.contributor.author | Sheng, Zhi | |
dc.contributor.author | Wang, Shu-Zong | |
dc.contributor.author | Green, Michael R. | |
dc.date | 2022-08-11T08:10:16.000 | |
dc.date.accessioned | 2022-08-23T17:01:54Z | |
dc.date.available | 2022-08-23T17:01:54Z | |
dc.date.issued | 2009-02-21 | |
dc.date.submitted | 2011-04-19 | |
dc.identifier.citation | EMBO J. 2009 Apr 8;28(7):866-76. Epub 2009 Feb 19. <a href="http://dx.doi.org/10.1038/emboj.2009.35">Link to article on publisher's site</a> | |
dc.identifier.issn | 0261-4189 (Linking) | |
dc.identifier.doi | 10.1038/emboj.2009.35 | |
dc.identifier.pmid | 19229297 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/44107 | |
dc.description.abstract | Lipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR-ABL activates 24p3 and represses 24p3R expression. Thus, BCR-ABL(+) cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R-containing cells but not in BCR-ABL(+) cells. The cell signalling and transcription factor pathways by which BCR-ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR-ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR-ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR-ABL is a critical feature of the mechanism by which imatinib kills BCR-ABL(+) cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR-ABL and are directly relevant to the treatment of BCR-ABL(+) disease. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19229297&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670863/pdf/emboj200935a.pdf | |
dc.subject | Animals | |
dc.subject | Core Binding Factor Alpha 2 Subunit | |
dc.subject | Down-Regulation | |
dc.subject | Female | |
dc.subject | Fusion Proteins, bcr-abl | |
dc.subject | Humans | |
dc.subject | Lipocalins | |
dc.subject | Male | |
dc.subject | Mice | |
dc.subject | Mice, Inbred Strains | |
dc.subject | Mice, SCID | |
dc.subject | Piperazines | |
dc.subject | Promoter Regions, Genetic | |
dc.subject | Proto-Oncogene Proteins p21(ras) | |
dc.subject | Pyrimidines | |
dc.subject | Receptors, Cell Surface | |
dc.subject | *Signal Transduction | |
dc.subject | *Transcription, Genetic | |
dc.subject | Genetics and Genomics | |
dc.title | Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R | |
dc.type | Journal Article | |
dc.source.journaltitle | The EMBO journal | |
dc.source.volume | 28 | |
dc.source.issue | 7 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/pgfe_pp/81 | |
dc.identifier.contextkey | 1946736 | |
html.description.abstract | <p>Lipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR-ABL activates 24p3 and represses 24p3R expression. Thus, BCR-ABL(+) cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R-containing cells but not in BCR-ABL(+) cells. The cell signalling and transcription factor pathways by which BCR-ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR-ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR-ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR-ABL is a critical feature of the mechanism by which imatinib kills BCR-ABL(+) cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR-ABL and are directly relevant to the treatment of BCR-ABL(+) disease.</p> | |
dc.identifier.submissionpath | pgfe_pp/81 | |
dc.contributor.department | Program in Molecular Medicine | |
dc.contributor.department | Programs in Gene Function and Expression | |
dc.source.pages | 866-76 |